Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Auxogyn, Merck KGaA sales and marketing update

    Auxogyn Inc., Menlo Park, Calif. Merck KGaA (Xetra:MRK), Darmstadt, Germany Business: Diagnostic Auxogyn granted Merck's Merck Serono S.A. unit exclusive rights to commercialize Auxogyn's Early Embryo Viability …

    Published on 4/14/2014
  • BioAlliance, Vestiq sales and marketing update

    BioAlliance Pharma S.A. (Euronext:BIO), Paris, France Vestiq Pharmaceuticals Inc., Morrisville, N.C. Business: Infectious BioAlliance terminated a 2012 deal that granted Vestiq exclusive rights in the U.S. to …

    Published on 4/14/2014
  • Cancer Genetics sales and marketing update

    Cancer Genetics Inc. (NASDAQ:CGIX), Rutherford, N.J. Business: Diagnostic Cancer Genetics launched its CALR mutation analysis test to help diagnose patients with essential thrombocythemia and primary myelofibrosis. The …

    Published on 4/14/2014
  • Cepheid sales and marketing update

    Cepheid Inc. (NASDAQ:CPHD), Sunnyvale, Calif. Business: Diagnostic Cepheid launched its Xpert Norovirus test in countries that recognize CE Mark approval to identify and differentiate Norovirus genogroup I and II. The …

    Published on 4/14/2014
  • Dainippon Sumitomo sales and marketing update

    Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Business: Neurology Dainippon's Sunovion Pharmaceuticals Inc. subsidiary launched Aptiom eslicarbazepine in the U.S. as an add-on therapy to treat partial-…

    Published on 4/14/2014
  • Immdal Ltd., Medigene sales and marketing update

    Immdal Ltd., Dublin, Ireland Medigene AG (Xetra:MDG), Martinsried, Germany Business: Infectious Medigene granted Immdal's Kora Healthcare subsidiary exclusive commercialization rights to Veregen sinecatechins in the U.K…

    Published on 4/14/2014
  • MDxHealth, Long Island Pathology Inc. sales and marketing update

    MDxHealth S.A. (Euronext:MDXH), Liege, Belgium Long Island Pathology Inc., East Setauket, N.Y. Business: Diagnostic MDxHealth granted Long Island Pathology non-exclusive co-marketing rights in the New York metropolitan …

    Published on 4/14/2014
  • Meda, Valeant Pharmaceuticals sales and marketing update

    Meda AB (SSE:MEDAA), Solna, Sweden Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), Montreal, Quebec Business: Neurology, Dermatology This quarter, Meda and Valeant will terminate their joint …

    Published on 4/14/2014
  • NanoString sales and marketing update

    NanoString Technologies Inc. (NASDAQ:NSTG), Seattle, Wash. Business: Diagnostic NanoString launched the nCounter PanCancer Pathways Panel, a gene expression assay that analyzes 770 genes in 13 cancer pathways for …

    Published on 4/14/2014
  • Response Genetics sales and marketing update

    Response Genetics Inc. (NASDAQ:RGDX), Los Angeles, Calif. Business: Pharmacogenetics Response Genetics said six U.S. healthcare plans across 10 states agreed to cover the biotech's portfolio of predictive genomic …

    Published on 4/14/2014
  • Swedish Orphan Biovitrum, TiGenix sales and marketing update

    Swedish Orphan Biovitrum AB (SSE:SOBI), Stockholm, Sweden TiGenix N.V. (Euronext:TIG), Leuven, Belgium Business: Musculoskeletal TiGenix granted Swedish Orphan Biovitrum exclusive commercialization rights to …

    Published on 4/14/2014
  • Vanda sales and marketing update

    Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), Washington, D.C. Business: Neurology Vanda launched Hetlioz tasimelteon in the U.S. to treat non-24-hour sleep wake disorder in totally blind patients. The wholesale acquisition…

    Published on 4/14/2014
  • Amarin, Kowa sales and marketing update

    Amarin Corp. plc (NASDAQ:AMRN), Dublin, Ireland Kowa Co. Ltd., Nagoya, Japan Business: Endocrine/Metabolic Amarin granted Kowa's Kowa Pharmaceuticals America Inc. subsidiary U.S. co-promotion rights to …

    Published on 4/7/2014
  • Bayer sales and marketing update

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Endocrine/Metabolic Bayer launched Jaydess low-dose levonorgestrel-releasing intrauterine system in the U.K. as a long-term contraceptive. The product, which costs 69…

    Published on 4/7/2014
  • HRA Pharma, Afaxys Inc. sales and marketing update

    HRA Pharma S.A., Paris, France Afaxys Inc., Charleston, S.C. Business: Genitourinary The Afaxys Pharmaceuticals division of Afaxys relaunched emergency contraceptive ella ulipristal acetate in the U.S. Afaxys has …

    Published on 4/7/2014
  • Intelligent Medical Devices, Abbott sales and marketing update

    Intelligent Medical Devices Inc., Waltham, Mass. Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Business: Diagnostic Intelligent Medical launched the IMDx VanR for Abbott m2000 test in Canada and Singapore to detect …

    Published on 4/7/2014
  • Jazz Pharmaceuticals sales and marketing update

    Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland Business: Hepatic Jazz launched Defitelio defibrotide in Germany and Austria to treat severe hepatic veno-occlusive disease (VOD) in adults and children undergoing…

    Published on 4/7/2014
  • Machaon sales and marketing update

    Machaon Diagnostics Inc., Oakland, Calif. Business: Diagnostic Machaon launched its aHUS Genetic Panel to genetically confirm atypical hemolytic uremic syndrome (aHUS). The company said the test, which costs $2,978, has…

    Published on 4/7/2014
  • Opko sales and marketing update

    Opko Health Inc. (NYSE:OPK; Tel Aviv:OPK), Miami, Fla. Business: Diagnostic Opko launched 4Kscore Prostate Cancer Test in the U.S. The laboratory developed test (LDT), which uses a panel of kallikrein biomarkers to …

    Published on 4/7/2014
  • Otsuka Pharmaceutical sales and marketing update

    Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Business: Diagnostic On April 14, Otsuka will launch its QuickNavi Strep A rapid test kit in Japan to detect beta-hemolytic Group A Streptococcus infection.

    Published on 4/7/2014
  • Saladax sales and marketing update

    Saladax Biomedical Inc., Bethlehem, Pa. Business: Diagnostic Saladax's Saladax Biomedical Laboratories division launched the My5-FU diagnostic test in the U.S. to personalize and optimize 5-fluorouracil (5-FU) dosing. …

    Published on 4/7/2014
  • Sequenom, Synapse Diagnostics sales and marketing update

    Sequenom Inc. (NASDAQ:SQNM), San Diego, Calif. Synapse Diagnostics, Hyderabad, India Business: Diagnostic Synapse launched Sequenom's MaterniT21 Plus LDT in India. The non-invasive prenatal fetal trisomy 21, 18 and 13 …

    Published on 4/7/2014
  • XDx Inc sales and marketing update

    XDx Inc., Brisbane, Calif. Business: Diagnostic XDx said health insurer Cigna Corp. (NYSE:CI, Bloomfield, Conn.) issued a positive coverage decision for XDx's AlloMap Molecular Expression Test for patients from six …

    Published on 4/7/2014
  • Ambry Genetics sales and marketing update

    Ambry Genetics Corp., Aliso Viejo, Calif. Business: Diagnostic Ambry launched the ExomeNext and ExomeNext-Rapid assays for exome sequencing in a clinical setting. ExomeNext has a list price of $5,800 and provides …

    Published on 3/31/2014
  • AstraZeneca sales and marketing update

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Gastrointestinal AstraZeneca launched Nexium Direct, a program that provides U.S. patients the option to order Nexium esomeprazole to treat gastroesophageal …

    Published on 3/31/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993